Characteristics of lupus and lupus nephritis at a tertiary care center in Lebanon

dc.contributor.authorKoubar, Sahar Hassan
dc.contributor.authorKort, Jeries
dc.contributor.authorKawtharani, Sarah
dc.contributor.authorShaya, Monique
dc.contributor.authorMakki, Maha H.
dc.contributor.authorUthman, Imad W.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentEpidemiology and Population Health (EPHD)
dc.contributor.departmentClinical Research Institute
dc.contributor.departmentDivision of Nephrology and Hypertension
dc.contributor.departmentBiostatistics Unit (BSU)
dc.contributor.departmentDivision of Allergy, Immunology and Rheumatology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.facultyFaculty of Health Sciences (FHS)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:55:20Z
dc.date.available2025-01-24T11:55:20Z
dc.date.issued2019
dc.description.abstractIntroduction: Systemic lupus erythematosus affects 4.8–78.5 people per 100,000 worldwide, 90% of whom are females. Geography and ethnicity have been shown to significantly affect the prevalence and natural history of the disease. Lupus nephritis affects around half of patients with systemic lupus erythematosus. Data about systemic lupus erythematosus and lupus nephritis in the Middle East are still scarce. In this study, we aimed to describe the characteristics of systemic lupus erythematosus and lupus nephritis at a tertiary care center in Lebanon. Methods: This is a retrospective chart review of all biopsy-proven lupus nephritis patients admitted to the American University of Beirut medical center between January 2000 and December 2018. Patients above 12 years of age who had any International Society of Nephrology/Renal Pathology Society (ISN/RPS) class of lupus nephritis on their renal biopsy were included in the study. Results: The study included 55 patients with lupus nephritis. Upon presentation of systemic lupus erythematosus, the most common clinical feature was arthritis, seen in 83% of patients, followed by anemia (82%) and malar rash (48%). In total 93% had positive ANA, 89% had positive anti-dsDNA and 98% of patients had proteinuria. The most common ISN/RPS class of lupus nephritis in our series was IV (49%). At the time of the biopsy 15% of patients underwent dialysis. At 6 months, 11/27 had complete remission, 6/27 had partial remission and 10/27 had no remission. At 1 year, 8/23 had complete remission, 4/23 had partial remission and 11/23 had no remission. During the study period, 15 out of 35 patients available for analysis had chronic kidney disease (CKD) and six out of 34 patients developed end-stage kidney disease requiring renal replacement therapy. In comparison to other series in the region, our series had more males affected, higher creatinine at the time of biopsy and greater degree of proteinuria. Conclusion: Our study provided insight on the demographics, characteristics, and outcomes of lupus nephritis in Lebanon. Interestingly, male gender was present in a quarter of patients. This warrants further investigation and confirmation. We are hoping to expand this experience into a national prospective registry to further characterize this entity in our region. © The Author(s) 2019.
dc.identifier.doihttps://doi.org/10.1177/0961203319877459
dc.identifier.eid2-s2.0-85074746600
dc.identifier.pmid31554458
dc.identifier.urihttp://hdl.handle.net/10938/31200
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.relation.ispartofLupus
dc.sourceScopus
dc.subjectGlomerulonephritis
dc.subjectLebanon
dc.subjectLupus nephritis
dc.subjectRenal biopsy
dc.subjectSle
dc.subjectAdolescent
dc.subjectAdult
dc.subjectBiopsy
dc.subjectFemale
dc.subjectHumans
dc.subjectKidney failure, chronic
dc.subjectLupus erythematosus, systemic
dc.subjectMale
dc.subjectMiddle aged
dc.subjectRenal dialysis
dc.subjectRenal insufficiency, chronic
dc.subjectRetrospective studies
dc.subjectTertiary care centers
dc.subjectYoung adult
dc.subjectAntinuclear antibody
dc.subjectAzathioprine
dc.subjectCardiolipin antibody
dc.subjectComplement
dc.subjectCreatinine
dc.subjectCyclophosphamide
dc.subjectCyclosporine
dc.subjectDouble stranded dna antibody
dc.subjectLupus anticoagulant
dc.subjectMycophenolate mofetil
dc.subjectRituximab
dc.subjectSm antibody
dc.subjectSteroid
dc.subjectAnemia
dc.subjectArthritis
dc.subjectArticle
dc.subjectChronic kidney failure
dc.subjectClinical feature
dc.subjectComparative study
dc.subjectCreatinine blood level
dc.subjectEnd stage renal disease
dc.subjectGlomerulus filtration rate
dc.subjectHematuria
dc.subjectHuman
dc.subjectImmunopathology
dc.subjectInflammation
dc.subjectKidney biopsy
dc.subjectLeukopenia
dc.subjectLupus erythematosus nephritis
dc.subjectLymphocytopenia
dc.subjectMaintenance therapy
dc.subjectMajor clinical study
dc.subjectMedical record review
dc.subjectMembranous glomerulonephritis
dc.subjectMental disease
dc.subjectMouth ulcer
dc.subjectNephrotic syndrome
dc.subjectOutcome assessment
dc.subjectPhotosensitivity
dc.subjectPriority journal
dc.subjectProteinuria
dc.subjectRash
dc.subjectRemission
dc.subjectRenal replacement therapy
dc.subjectRetrospective study
dc.subjectSeizure
dc.subjectSteroid therapy
dc.subjectSystemic lupus erythematosus
dc.subjectTertiary care center
dc.subjectThrombocytopenia
dc.subjectHemodialysis
dc.subjectPathophysiology
dc.titleCharacteristics of lupus and lupus nephritis at a tertiary care center in Lebanon
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019-3699.pdf
Size:
196.79 KB
Format:
Adobe Portable Document Format